Sequentia Biotech
PrivateLast Round
Series A
Sep 30, 2024
Total Funding Raised
$11.26M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sequentia Biotech operates in Healthcare & Life Sciences and is based in Barcelona. Its latest recorded funding round was a Series A round in September 2024.
Sequentia Biotech is a bioinformatics company that provides solutions for the interpretation of biological data.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Healthcare Analytics, Precision Medicine, Drug Discovery, Vertical SaaS
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Usage-Based SaaS, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sequentia Biotech Comparables
Compare Sequentia Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cmbio | 79% | |
| ClairLabs | 77% | |
| Reliance Industries | 77% |
For institutional investors. Book with your work email.
Sequentia Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 30, 2024 | ||||
| Grant | Oct 6, 2021 | ||||
| Grant | Jul 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sequentia Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Union's Horizon Research and Innovation program | Grant |
| EIC Accelerator | Grant |
| Seventure Partners | Series A |
| EIC Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 3, 2026
Open roles increased to 9, 2.3x the trailing average.
- Feb 22, 2026
Grew 25% QoQ, from 36 to 45 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 9, 2026
Sequentia Biotech SL launches AVIZ, the AIR(R) Quantification Explorer, on Oct 9th '26, enabling researchers to explore and visualize RNA-Seq results, review samples, analyze differential expression, and investigate biological pathways within the AIR(R) cloud platform.
For institutional investors. Book with your work email.
Sequentia Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sequentia Biotech's valuation, stock price, and market status.
Is Sequentia Biotech a public or private company?
Sequentia Biotech is a private company.
What is the current stock price of Sequentia Biotech?
Sequentia Biotech is a private company, so its shares have no public market price. Caplight tracks Sequentia Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sequentia Biotech worth (valuation)?
Valuation information for Sequentia Biotech is not publicly available.
Can I buy Sequentia Biotech stock?
Sequentia Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sequentia Biotech's last funding round?
Sequentia Biotech's most recent funding round was Series A on September 30, 2024.
Who are the main investors in Sequentia Biotech?
Key investors in Sequentia Biotech include Seventure Partners.
Will Sequentia Biotech IPO soon?
No public IPO plans have been announced for Sequentia Biotech.
How can I track Sequentia Biotech secondary market activity?
Caplight tracks bids, offers, and trades in Sequentia Biotech's shares on secondary markets.